Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China

Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China

ObjectiveThis study aimed to investigate the association between the utilization of Sodium-dependent glucose cotransporters inhibitors (SGLT2i) in real-world settings and kidney outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) in mainland China.MethodsIn a retrospecti...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiang Xiao, Shuming Ji, Tao Zheng, Tianzhu Wang, Dapeng Jiang, Fang Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Pharmacology
Subjects:	type 2 diabetes diabetic kidney disease sodium-glucose transport protein 2 (SGLT2) inhibitors real world study outcomes
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1468435/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The association between the utilization of SGLT2 inhibitors and diabetic retinopathy; a systematic review and meta-analysis of cohort studies
by: Shahriar Barkhordari, et al.
Published: (2024-06-01)

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes
by: Naveenkumar Nallathambi, et al.
Published: (2024-11-01)

Antihypertensive effects of SGLT2 inhibitors; a letter to the editor on new concepts
by: Rahimeh Eskandarian, et al.
Published: (2024-06-01)

Diabetic ketoacidosis induced by SGLT2 inhibitors in acute ischemic stroke: a report of two cases
by: Jin-Heon Jeong
Published: (2024-12-01)

SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review
by: Michał Szczepański, et al.
Published: (2024-12-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors
by: Selin Genc, et al.
Published: (2024-11-01)

Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials
by: Ying Liu, et al.
Published: (2025-01-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)

New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia
by: Cheng-Hsien Hung, et al.
Published: (2024-12-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

SGLT‐2 inhibitors and high‐dose acarbose as potential high‐risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series
by: Wei Qiang, et al.
Published: (2024-09-01)

Assessment of the Utilization of Sodium–Glucose Cotransporter-2 Inhibitors in Patients Without Diabetes
by: Takuma Koinuma, et al.
Published: (2024-12-01)

Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights
by: Han-Sang Baek, et al.
Published: (2024-11-01)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024-11-01)

The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients
by: Yibin Zhang, et al.
Published: (2024-12-01)

Safety of SGLT2 Inhibitors and Urinary Tract Infections in Clinical Practice—A Cross-Sectional Study
by: Liana Iordan, et al.
Published: (2024-12-01)

Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model
by: Amarit Tansawet, et al.
Published: (2024-11-01)

Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells
by: Aiko Seki, et al.
Published: (2025-01-01)

BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors
by: Betül SÜMBÜL ŞEKERCİ, et al.
Published: (2025-01-01)

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
by: Xiaoyan Liang, et al.
Published: (2025-01-01)

The immunohistochemical combination of low SGLT2 expression and high PRDX4 expression independently predicts shortened survival in patients undergoing surgical resection for hepatoblastoma
by: Yao Liu, et al.
Published: (2025-01-01)

SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms
by: Ya-ru Chen, et al.
Published: (2024-12-01)

Analysis of the Endocrine Responses to Anti-Diabetes Drugs: An Issue of Elevated Plasma Renin Concentration in Sodium-Glucose Co-Transporter 2 Inhibitor
by: Lin CW, et al.
Published: (2025-01-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications
by: Aldona Sokołowska, et al.
Published: (2025-01-01)

A cost-utility analysis of adding SGLT2 inhibitors for the management of type 2 diabetes with chronic kidney disease in Thailand
by: Natthakan Chitpim, et al.
Published: (2025-01-01)

SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes
by: Yun Wen, et al.
Published: (2024-12-01)

Advances in sodium-glucose transporter protein 2 inhibitors and tumors
by: Jiaqi Wang, et al.
Published: (2025-02-01)

The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives—A Narrative Review
by: Giuseppe Miceli, et al.
Published: (2024-11-01)

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01)

Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes
by: Xuehong Li, et al.
Published: (2024-11-01)

Evaluation and comparison of efficacy and safety of tirzepatide, liraglutide and SGLT2i in patients with type 2 diabetes mellitus: a network meta-analysis
by: Yunjie Teng, et al.
Published: (2024-12-01)

Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
by: Min-Jia Cao, et al.
Published: (2025-01-01)

Real-World Assessment of Efficacy and Safety Parameters for Dapagliflozin in Management of Type 2 Diabetes Mellitus: REWARD Study
by: Ahmed Hassoun, et al.
Published: (2022-01-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
by: Nicia I. Profili, et al.
Published: (2024-10-01)

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes
by: Xie H, et al.
Published: (2024-11-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report
by: Diana Alegre-González, et al.
Published: (2025-10-01)